Neurochem News
Most Popular Neurochem Story
Neurochem hammered on Alzhemed failure
The analysts swiftly began writing off Neurochem's Alzhemed after the company announced last night that its lead drug had failed a late-stage trial for Alzheimer's. The news sent Neurochem's stock Read more...
Latest Headlines
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
